BlackRock, Inc. 13D and 13G filings for Regeneron Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-25 4:59 pm Sale | 2023-12-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN | BlackRock Inc. BLK | 8,629,707 8.100% | -537,110 (-5.86%) | Filing |
| 2023-02-03 4:27 pm Sale | 2022-12-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN | BlackRock Inc. BLK | 9,166,817 8.600% | -444,054 (-4.62%) | Filing |
| 2022-02-01 5:08 pm Sale | 2021-12-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN | BlackRock Inc. BLK | 9,610,871 9.100% | -165,315 (-1.69%) | Filing |
| 2021-02-01 08:23 am Purchase | 2020-12-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN | BlackRock Inc. BLK | 9,776,186 9.300% | 3,637,338 (+59.25%) | Filing |